Experienced pharma exec joins the business’ management board.
BioNTech has appointed James Ryan, PhD, to the management board as chief legal officer (CLO), effective Sept. 1. He will continue to lead the company’s corporate legal strategy and global legal operations, including transactions, corporate governance, securities, intellectual property (IP), insurance, data privacy, among others. Prior to his appointment to the board, James Ryan served as the company’s general counsel and SVP, Legal & IP.
He has nearly 20 years of global legal and IP expertise in the pharma industry. He joined BioNTech in July 2018. Since then, he has guided the company through various key business, IP, and transactional activities.
“We are looking forward to welcoming James Ryan to the management board. Since joining BioNTech in 2018, he has been a trusted advisor and a proven senior leader, given his extensive global experience across key healthcare legal and compliance domains,” comments Helmut Jeggle, Chairman of the BioNTech supervisory board. “ … He combines scientific and legal expertise in an extraordinary manner, contributing to BioNTech’s continued success and growth trajectory. We also value James for his contributions to strengthen BioNTech’s unique culture and his commitment to continue to do so in the future.”
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.